Apr. 1 at 8:01 PM
$OCUL What is next? Vegas : « Let us explain that the so-called floaters are simply visible hydrogel dissolution fragments, proof that the drug is working exactly as designed, in the periphery, outside the visual axis, never seen by patients, and not a safety signal of any kind ». And let us also recall that an 18.3% superiority margin over the current standard of care, achieved in the most visually stable, hardest-to-impress patient population ever enrolled in a wet AMD Phase 3 trial, is not a modest efficacy signal; it is the largest head-to-head superiority gap ever demonstrated against an anti-VEGF in the history of retinal disease.
